Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20152894 | 0.85 | KDM4E (0.50) | RIPK1KDM4ECYP2C19USP2HPGD | |
| SCHEMBL15751660 | 0.85 | KDM4E (0.68) | RIPK1KDM4ECYP2C19USP2HPGD | |
| SCHEMBL20425004 | 0.84 | KDM4E (0.49) | RIPK1KDM4ECYP2C19USP2HPGD | |
| SCHEMBL18255044 | 0.83 | KDM4E (0.57) | RIPK1KDM4ECYP2C19HCRTR2HPGD | |
| SCHEMBL12639917 | 0.81 | KDM4E (0.72) | KDM4ECYP2C19HPGDTP53 | |
| SCHEMBL23851037 | 0.81 | RIPK1 (0.51) | RIPK1KDM4ECYP2C19TP53 | |
| SCHEMBL28410232 | 0.81 | RIPK1 (0.51) | RIPK1KDM4ECYP2C19HCRTR2SLC6A9 | |
| SCHEMBL12036196 | 0.81 | KDM4E (0.46) | KDM4ECYP2C19USP2HPGDNPSR1 | |
| SCHEMBL16769733 | 0.80 | HRH3 (0.55) | KDM4EHPGDHSD17B10SLC6A9 | |
| SCHEMBL21868474 | 0.80 | KDM4E (0.60) | RIPK1KDM4ECYP2C19HCRTR2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | RIPK1 414/4885KDM4E 649/4885CYP2C19 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.